The Future of Melanoma: What to Anticipate in 2023 with Neoadjuvant and Adjuvant Pembrolizumab

AACR 2023 highlights on advances in the treatment of resected high-risk melanoma with Jeffrey WeberПодробнее

Advances in utilizing neoadjuvant immunotherapy in melanomaПодробнее

Melanoma | 2022 OneOncology ConferenceПодробнее

Adjuvant therapy for high-risk melanomaПодробнее

Highlights in melanoma at AACR 2023Подробнее

Expert Report on novel data in (neo)adjuvant treatment of melanoma from ASCO 2022Подробнее

Neoadjuvant Therapy and Adjuvant Therapy (pre and post-surgery) for MelanomaПодробнее

The Future of Melanoma: What to Anticipate in 2022Подробнее

#ESMO22 Highlights on neoadj. vs adjuvant pembrolizumab in resected stage III-IV melanoma:SWOG S1801Подробнее

The personalization of neoadjuvant immunotherapy in stage III melanomaПодробнее

The future of adjuvant therapy in melanomaПодробнее

Adjuvant and Neoadjuvant Therapy for Stage II and III MelanomaПодробнее

Results from KEYNOTE-716: adjuvant therapy with pembrolizumab in high-risk stage II melanomaПодробнее

How Melanoma is Treated in 2023Подробнее

Adjuvant and neoadjuvant clinical trials for melanomaПодробнее

KEYNOTE-716: adjuvant pembrolizumab for high-risk melanomaПодробнее

WCH23: What’s New and Hot in MelanomaПодробнее

Gamma signature guidance in optimizing neoadjuvant immunotherapy for resectable melanomaПодробнее

KEYNOTE-716: safety profile and results of pembrolizumab for melanomaПодробнее